Journal Article > ResearchFull Text
Lancet. 2018 May 1; Volume 391 (Issue 10133); DOI:10.1016/S0140-6736(17)33050-7
Lessler J, Moore SM, Luquero FJ, McKay H, Grais RF, et al.
Lancet. 2018 May 1; Volume 391 (Issue 10133); DOI:10.1016/S0140-6736(17)33050-7
Cholera remains a persistent health problem in sub-Saharan Africa and worldwide. Cholera can be controlled through appropriate water and sanitation, or by oral cholera vaccination, which provides transient (∼3 years) protection, although vaccine supplies remain scarce. We aimed to map cholera burden in sub-Saharan Africa and assess how geographical targeting could lead to more efficient interventions.
Journal Article > Short ReportFull Text
Emerg Infect Dis. 2015 January 1; Volume 21 (Issue 1); DOI:10.3201/eid2101.140256
Gamougam K, Daugla DM, Toralta J, Ngadoua C, Fermon F, et al.
Emerg Infect Dis. 2015 January 1; Volume 21 (Issue 1); DOI:10.3201/eid2101.140256
In 2011, vaccination with a serogroup A meningococcal polysaccharide conjugate vaccine was implemented in 3 of 23 regions in Chad. Cases of meningitis declined dramatically in vaccinated areas, but an epidemic continued in the rest of Chad. In 2012, the remaining Chad population was vaccinated, and the epidemic was halted.
Journal Article > ResearchFull Text
Lancet. 2014 January 4; Volume 383 (Issue 9911); DOI:10.1016/S0140-6736(13)61612-8
Daugla DM, Gami JP, Gamougam K, Naibei N, Mbainadji L, et al.
Lancet. 2014 January 4; Volume 383 (Issue 9911); DOI:10.1016/S0140-6736(13)61612-8
A serogroup A meningococcal polysaccharide-tetanus toxoid conjugate vaccine (PsA-TT, MenAfriVac) was licensed in India in 2009, and pre-qualified by WHO in 2010, on the basis of its safety and immunogenicity. This vaccine is now being deployed across the African meningitis belt. We studied the effect of PsA-TT on meningococcal meningitis and carriage in Chad during a serogroup A meningococcal meningitis epidemic.